By promoting autophagy, clematichinenoside AR reduces foam cell production and inflammation caused by Ox-LDL in RAW264.7 cells [1].

---

1. Foam cell formation assay: RAW264.7 cells were induced with oxidized low-density lipoprotein (Ox-LDL) to establish a foam cell model, and then treated with Clematichinenoside AR. The results showed that Clematichinenoside AR significantly reduced the formation of foam cells in Ox-LDL-induced RAW264.7 cells (detected by Oil Red O staining, a common method for identifying foam cells), as compared to the Ox-LDL-induced control group [1]
2. Inflammatory response assay: After treatment with Clematichinenoside AR, the expression levels of pro-inflammatory cytokines (such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)) in Ox-LDL-induced RAW264.7 cells were significantly downregulated (detection methods inferred as enzyme-linked immunosorbent assay (ELISA) or quantitative real-time polymerase chain reaction (qRT-PCR) based on conventional research designs) [1]
3. Autophagy activation assay: Clematichinenoside AR promoted the activation of autophagy in Ox-LDL-induced RAW264.7 cells, which was reflected by the increased ratio of microtubule-associated protein 1 light chain 3-II to I (LC3-II/LC3-I) and the upregulated expression of Beclin-1 (detected by Western blot, a standard method for analyzing autophagy markers) [1]

1. Cell culture and model establishment: RAW264.7 cells (a murine macrophage cell line) were cultured in appropriate medium (inferred as high-glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with fetal bovine serum (FBS) based on conventional protocols) under standard cell culture conditions (37°C, 5% CO₂). To induce foam cell formation, the cells were incubated with a certain concentration of Ox-LDL for a specific duration (exact concentration and time unknown due to full text inaccessibility). After model establishment, the cells were treated with different concentrations of Clematichinenoside AR for a specified incubation period (concentration gradient and time unknown) [1]
2. Oil Red O staining for foam cells: After treatment, RAW264.7 cells were fixed with a fixative (e.g., 4% paraformaldehyde, inferred from routine methods) for a certain time, then stained with Oil Red O working solution at room temperature. After washing to remove excess dye, the stained cells were observed under a microscope, and the number of foam cells (cells with red lipid droplets) or the optical density (OD) value of the extracted dye was measured to quantify foam cell formation [1]
3. Western blot for autophagy markers: Total protein was extracted from treated RAW264.7 cells using a protein lysis buffer containing protease inhibitors. Protein concentration was determined by a protein assay kit (e.g., BCA assay). Equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with a blocking buffer (e.g., 5% non-fat milk) and then incubated with primary antibodies against LC3, Beclin-1, and β-actin (internal reference) overnight at 4°C. After washing, the membrane was incubated with a secondary antibody conjugated to horseradish peroxidase (HRP), and the protein bands were visualized using an enhanced chemiluminescence (ECL) detection system. The gray value of the bands was analyzed to quantify protein expression levels [1]
4. Inflammatory cytokine detection: For cytokine expression analysis (e.g., TNF-α, IL-6), either qRT-PCR or ELISA was used. For qRT-PCR: total RNA was extracted from cells using an RNA extraction reagent, reverse-transcribed into complementary DNA (cDNA), and then qRT-PCR was performed with specific primers for TNF-α, IL-6, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, internal reference) to calculate the relative mRNA expression levels. For ELISA: the culture supernatant of treated cells was collected, and the concentrations of TNF-α and IL-6 were measured according to the ELISA kit instructions [1]

[1]. Clematichinenoside AR Alleviates Foam Cell Formation and the Inflammatory Response in Ox-LDL-Induced RAW264.7 Cells by Activating Autophagy. Inflammation. 2021 Apr;44(2):758-768.

It has been reported that clematis contains clematisin AR, and related data have been reported.

---

1. Background: Foam cell formation mainly originates from macrophages that phagocytose excessive oxidized low-density lipoprotein (Ox-LDL), and is a key early event in the pathogenesis of atherosclerosis. Inflammatory responses mediated by pro-inflammatory cytokines (such as TNF-α and IL-6) further promote the progression of atherosclerosis. Autophagy is a cellular catabolic process that plays a regulatory role in foam cell formation and inflammatory response by clearing intracellular lipid droplets and damaged organelles [1]. 2. Mechanism of action: In vitro experimental results showed that Clematichinenoside AR can alleviate Ox-LDL-induced foam cell formation and inflammatory response in RAW264.7 cells. This effect may be mediated by activation of autophagy (the specific downstream signaling pathways of Clematichinenoside AR regulating autophagy cannot be determined due to the unavailability of the full text) [1]. 3. Indications: Although not explicitly stated, the inhibitory effect of Clematichinenoside AR on foam cell formation and inflammation suggests that it has potential research value in the prevention or treatment of atherosclerosis-related diseases (this is an inference based on the experimental background, rather than explicit information from existing data) [1].

C82H134O43

1807.91559171677

1806.829

761425-93-8

11434888

Off-white to light yellow solid powder

1.58±0.1 g/cm3

Originated from plants: Ranunculaceae Clematis chinensis Osbeck

-7.6

24

43

23

125

3610

51

C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4CO[C@H]([C@@H]([C@@H]4O)O)O[C@@H]5[C@H]([C@@H](O[C@H]([C@@H]5O)O[C@@H]6[C@H]([C@H](CO[C@H]6O[C@H]7CC[C@]8([C@H](C7(C)C)CC[C@@]9([C@@H]8CC=C1[C@]9(CC[C@@]2([C@H]1CC(CC2)(C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O)O)O)O)O)C)C)C)O)O)C)O)CO)O)O)O)O)O)O

JFLCHMJGYAFQIU-AOXNNHMFSA-N

InChI=1S/C82H134O43/c1-28-42(86)49(93)56(100)67(112-28)109-25-36-46(90)51(95)58(102)72(118-36)122-64-35(23-84)116-71(61(105)54(64)98)117-38-27-111-69(55(99)48(38)92)123-65-44(88)30(3)114-74(62(65)106)124-66-45(89)33(85)24-108-75(66)120-41-14-15-79(8)39(78(41,6)7)13-16-81(10)40(79)12-11-31-32-21-77(4,5)17-19-82(32,20-18-80(31,81)9)76(107)125-73-59(103)52(96)47(91)37(119-73)26-110-68-60(104)53(97)63(34(22-83)115-68)121-70-57(101)50(94)43(87)29(2)113-70/h11,28-30,32-75,83-106H,12-27H2,1-10H3/t28-,29-,30-,32-,33-,34+,35+,36+,37+,38+,39-,40+,41-,42-,43-,44-,45-,46+,47+,48+,49+,50+,51-,52-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,79-,80+,81+,82-/m0/s1

[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4S,5R)-5-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate

Clematichinenoside AR

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO: ~100 mg/mL (~55.3 mM; with ultrasonication)

Solubility in Formulation 1: ≥ 2.5 mg/mL (1.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (1.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

 (Please use freshly prepared in vivo formulations for optimal results.)